0001759655TRUE00017596552024-05-222024-05-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K/A

(Amendment No. 1)
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2024
_________________________
Privia Health Group, Inc.
(Exact Name of Registrant as Specified in Its Charter)
_________________________
Delaware
001-4036581-3599420
(State or other jurisdiction of incorporation or organization)
(Commission
File No.)
(I.R.S. Employer Identification No.)
950 N. Glebe Rd.,
Suite 700
Arlington,Virginia22203
(Address of Principal Executive Offices)
(Zip Code)
(571) 366-8850
Registrant's telephone number, including area code
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Explanatory Note
On May 22, 2024, Privia Health Group, Inc. (the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”) disclosing, among other things, the results of its 2024 annual meeting of shareholders (the “Original Report”) held on May 22, 2024 (the “Annual Meeting”). This Current Report on Form 8-K/A amends and restates Item 5.07 of the Original Report to correct the voting results reported for Proposal No. 2, for which the number of Votes Against was inadvertently overstated in the Original Report.
As required by Rule 12b-15 under the Securities Exchange Act of 1934, the Company has set forth the complete text of Item 5.07 of the Original Report, as amended hereby.
Item 5.07 Submission of Matters to a Vote of Security Holders
On May 22, 2024, the Company held the Annual Meeting via live webcast. At the Annual Meeting, the Company’s stockholders approved all five proposals.
Proposal No. 1: Election of directors.
The following four nominees were elected to serve as Class II directors for a term expiring at the Company’s 2027 Annual Meeting of Stockholders, or until such director's respective successor is duly elected and qualified or such director's earlier death, resignation or removal.
NomineeVotes ForVotes WithheldBroker Non-Votes
Thomas McCarthy99,268,7463,905,96311,085,362
Parth Mehrotra102,934,5601,005,79110,319,720
Dr. Jaewon Ryu99,347,0553,827,65411,085,362
William (Bill) Sullivan65,283,93637,861,26711,114,868
Proposal No. 2: Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.
The Company’s stockholders approved, on a non-binding basis, the compensation of our named executive officers.
Votes For
Votes Against
Abstentions
Broker Non-Votes
96,616,303
2,663,618
4,660,430
10,319,720
Proposal No. 3: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
The appointment of PricewaterhouseCoopers LLP was ratified.
Votes ForVotes AgainstAbstentionsBroker Non-Votes
110,149,64795,3944,015,030—

Proposal No. 4: Amend and restate the Company’s amended and restated certificate of incorporation (the “Charter”) to remove supermajority voting standards.
The proposal to amend and restate the Charter to remove supermajority voting provisions was approved.
Votes ForVotes AgainstAbstentionsBroker Non-Votes
99,807,24796,8324,036,27210,319,720



Proposal No. 5: Amend and restate the Company’s Charter to allow for exculpation of officers as permitted by Delaware law.
The proposal to amend and restate the Charter to remove or limit the personal liability of officers to the extent permitted under the Delaware General Corporation Law was approved.
Votes ForVotes AgainstAbstentionsBroker Non-Votes
92,992,9746,924,3314,023,04510,319,721




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRIVIA HEALTH GROUP, INC.
Date: May 29, 2024
By:/s/ David Mountcastle
Name: David Mountcastle
Title: Executive Vice President, Chief Financial Officer and Authorized Officer


v3.24.1.1.u2
Cover
May 22, 2024
Cover [Abstract]  
Document Type 8-K/A
Document Period End Date May 22, 2024
Entity Registrant Name Privia Health Group, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40365
Entity Tax Identification Number 81-3599420
Entity Address, Address Line One 950 N. Glebe Rd.,
Entity Address, Address Line Two Suite 700
Entity Address, State or Province VA
Entity Address, City or Town Arlington,
Entity Address, Postal Zip Code 22203
City Area Code 571
Local Phone Number 366-8850
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol PRVA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001759655
Amendment Flag true
Amendment Description On May 22, 2024, Privia Health Group, Inc. (the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”) disclosing, among other things, the results of its 2024 annual meeting of shareholders (the “Original Report”) held on May 22, 2024 (the “Annual Meeting”). This Current Report on Form 8-K/A amends and restates Item 5.07 of the Original Report to correct the voting results reported for Proposal No. 2, for which the number of Votes Against was inadvertently overstated in the Original Report.As required by Rule 12b-15 under the Securities Exchange Act of 1934, the Company has set forth the complete text of Item 5.07 of the Original Report, as amended hereby.
Privia Health (NASDAQ:PRVA)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Privia Health.
Privia Health (NASDAQ:PRVA)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Privia Health.